LUMOLUMOS PHARMA, INC.

Nasdaq lumos-pharma.com


$ 2.26 $ -0.29 (-11.37 %)    

Wednesday, 15-May-2024 15:58:45 EDT
QQQ $ 452.83 $ 3.91 (0.87 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 3.17 (0.6 %)
TLT $ 92.14 $ 1.28 (1.41 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 2.24
$ 2.26
$ 0.00 x 0
$ 0.00 x 0
$ 2.26 - $ 2.26
$ 2.41 - $ 4.55
85,052
na
20.77M
$ -3.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-11-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-09-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 06-02-2020 03-31-2020 10-Q
18 03-03-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-05-2019 12-31-2018 10-K
23 11-02-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 03-05-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 03-06-2017 12-31-2016 10-K
31 11-08-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lumos-pharma-q1-2024-gaap-eps-129-misses-118-estimate-sales-16500k-miss-30260k-estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18...

 hc-wainwright--co-reiterates-buy-on-lumos-pharma-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.

 oppenheimer-maintains-outperform-on-lumos-pharma-maintains-16-price-target

Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and maintains $16 price target.

 hc-wainwright--co-reiterates-buy-on-lumos-pharma-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.

 lumos-pharma-q4-2023-gaap-eps-1170-misses-1150-estimate-sales-826000k-beat-1750k-estimate

Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.170) per share which missed the analyst consensus estimate of $(1.1...

 earnings-scheduled-for-march-7-2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

 earnings-preview-lumos-pharma
Earnings Preview: Lumos Pharma
03/06/2024 18:01:39

 oppenheimer-maintains-outperform-on-lumos-pharma-lowers-price-target-to-16

Oppenheimer analyst Leland Gershell maintains Lumos Pharma (NASDAQ:LUMO) with a Outperform and lowers the price target from ...

 hc-wainwright--co-reiterates-buy-on-lumos-pharma-maintains-28-price-target

HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma (NASDAQ:LUMO) with a Buy and maintains $28 price target.

 lumos-pharma-to-host-virtual-key-opinion-leader-webinar-to-discuss-phase-2-oragrowth-trial-data-and-treatment-potential-of-oral-lum-201-for-pediatric-growth-hormone-deficiency

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Gr...

 why-toast-shares-are-trading-lower-by-around-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday.

 why-is-biomarin--bridgebio-pharma-rival-lumos-pharma-stock-trading-higher-today

Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2...

 roblox-under-armour-gopro-nuvei-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks reco...

Core News & Articles

LUMO: 154% | Lumos Pharma Announces Topline Data From Phase 2 OraGrowtH210 And OraGrowtH212 Trials Of LUM-201 In PGHD Met All P...

 why-american-public-education-shares-are-trading-higher-by-around-21-here-are-20-stocks-moving-premarket

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7%...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION